期刊文献+

169例多囊肾临床研究 被引量:3

Clinic study on 169 cases of polycystic kidney
下载PDF
导出
摘要 目的对多囊肾病人进行必要的临床分期,并对去顶减压手术进行较为正确的评估。方法对169例多囊肾病例进行了分析。根据多囊肾病人的血压、肾功能、年龄将多囊肾分为三期,对手术病人手术前后临床症状、血压、肾功能进行了比较并随访。结果一、二期多囊肾病人术前血压平均为18.2/12.4、19.8/14.2kpa,BUN为9.8、12.1mmol/L,Cr为166、186μmol/L。术后血压平均为17.1/11.2、19.2/12kpa,BUN为8.2、10.1mmol/L,Cr为147、162μmol/L。经统计,手术前后患者血压、肾功能差异存在着显著性,而三期病人术前术后除临床症状有所改善外,其他无差异。有58例随访1~10年,其中一、二期病人52例,病情发展较为缓慢,临床症状明显改善。结论选择性的对一、二期病人进行去顶减压手术对改善症状,降低血压、延缓肾功能衰竭具有良好的效果。 [Objective] To evaluate the cystic decompression(CD) operation on polycystic kidney disease according to the clinical stage. [Methods] Three main parameters, age, blood pressure and renal function, were observed pre-operatively and post-operatively in 169 patients who took CD operation. Necessary follow-up was carried out. [Results] The preoperative mean blood pressure in 1st and 2nd stage were: 18.2/12.4 Kpa and 19.8/14.2 Kpa, BUN were 9.8 and 12.1 mmol/L, Cr were 16.6 and 18.6 μmol/L, respectively. After CD operation, blood pressures of the 1st and 2nd stage patients were 17.1/11.2 Kpa and 19.2/12.1 Kpa, BUN were 8.2 and 10.1 mmol/L Cr were 147 and 162 μmol/L, respectively. Statistic analysis found that there were obvious changes pre- and post-operatively in 1st and 2nd stage patients. For 3rd stage patients who took CD, there was subjective improvement on clinical symptoms, blood pressure and renal function. A follow-up of 58 patients (including 52 1st and 2nd stage patients) for 1-10 years showed that there was obvious improvement in clinic symptoms, and a slowdown of chronic renal failure progression. [Conclusion] For the 1st and 2nd stage polycystic kidney patients, CD operation can improve clinic symptoms, lower blood pressure and slowdown chronic renal failure.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2008年第2期206-208,共3页 China Journal of Modern Medicine
关键词 多囊肾 肾功能衰竭 去顶减压 polycystic kidney renal failure cystic decompression operation
  • 相关文献

参考文献9

  • 1HE SZ, AN SY, JIANG HM, et al. Exploration of polyeystic kidney disease decompression [J]. Chinese Journal of Surgery, 1979, 17(1): 60-62.
  • 2WOO D. Apoptosis and loss of renal tissue in polycystic kidney disease[J]. N Engl J Med, 1995, 333(1): 18-25.
  • 3MOCHIZUKI T, WU G, HAYASHI T, et al. PKD2, a gene for polyeystie kidney disease that encodes an integral membrane protein[J]. Science, 1996, 272(2): 1339-1342.
  • 4MEI CL, LI L.Development of molecular genetic mechanism and treatment of autosomal plyeystic kidney disease[J]. Chinese Journal of Nephrology Dialysis&Transplantation, 2001, 10 (5): 454-459.
  • 5EUNHEE SY, AHMED SS, DAVID LL, et al. Keratinocyte growth factor causes proliferation of urothlium in uiuo [J]. Jurol, 1995, 154(3): 1566-1570.
  • 6PETER DJ, BREUNING MH. Autosomal dominant polycystic kidney disease; modification of disease progression [J]. Lancet, 2001, 358(9291): 1439-1444.
  • 7KENNEFICK T, AL-NIMRI M, OYAMA T, et al. Hypertension and renal injury in experimental polycystic kidney disease [J]. Kidney Int, 1999, 56(9): 2181-2190.
  • 8DELL KM, NEMOR R, SWEENEY WE, et al. Anovel inhibitor of tumor necresis faetor_a convering enzyme meliorate polyeystie kidney disease[J]. Kidney Int, 2001, 60(7): 1240-1248.
  • 9WOO D, TABANCAY AJ, WANG C. Mierotubule active taxanes inhibit polycystic kidney disease progression in CPK mouse [J]. Kidney Int, 1997, 51(11): 1613-1618.

同被引文献16

  • 1张桂英.超声诊断双肾钙质沉淀症1例[J].中国超声医学杂志,2005,21(8):618-618. 被引量:3
  • 2Rossetti S, Harris PC. Genotype - phenotype correlations in autosomal dominant and autosomal recessive polycystic kidney disease [ J ]. Am Soc Nephrol,2007,18 (5) : 1374 - 1380.
  • 3Dai B, Liu Y, Mei C, Fu L, et al. Rosiglitazone attenuates development of polycystic kidney disease and prolongs the survival in Han: SPRD rats[J]. Clin Sci (Lond),201Q.
  • 4Pefico N, Antiga L, Caroli A, Ruggenenti P,et al. Sirolimus therapy to halt the progression of ADPKD[ J]. J Am Soc Nephrol,2010,21 (6) :1031 - 1040.
  • 5Rochester M. Prospects for mTOR inhibitor use in patients with pelycystic kidney disease and hamartomatous diseases[ J]. Clin J Am Soc Nephrol,2010,73 (6) :478 -481.
  • 6Vicente E, Peter C. Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseases [ J ]. Nature Clinical Practice Nephrology ,2006,2:40 - 55.
  • 7Ruggenenti P, Remuzzi A, Ondei P, et al. Safety and efficacy of long - acting somatostatin treatment in autosomal - dominant polycystic kidney disease[ J]. Kidney Int. ,2005,68 ( 1 ) :206 - 216.
  • 8李莉蕊,张鸿雁,王沭果.超声发现婴儿型多囊肾2例[J].中国医学影像技术,2007,23(11):1679-1679. 被引量:3
  • 9李胜利.胎儿畸形产前超声诊断学[M]北京:人民军医出版社,2006270.
  • 10赵婧.成人型多囊肾的超声诊断与分析[J].临床超声医学杂志,2007,9(12):761-762. 被引量:3

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部